抗小鼠CTLA-4单抗(9D9)在B16黑色素瘤模型中怎么给药?

Figure 1 The effect of anti-PD-1 and anti-CTLA-4 antibodies on the tumor growth in B16-F10-bearing mice. (A) A schematic diagram illustrating the chronological events of experiments (n=8). (B) Tumor growth kinetics in anti-PD-1 day 1-4-7, anti-PD-1 day 11-14-17 or anti-CTLA-4 day 1-4-7 treated B16-F10-bearing mice, compared with vehicle (n=2). Data are mean ± SEM. (C,D,E,F,G,H) The correlation of tumor size and tumor-infiltrating and splenic immune cell population infiltrating CD45+CD3+ (C), CD45+CD3+CD8+ T cells (D), CD45+CD3+CD4+ T cells (E) and CD45+CD11b+ myeloid cells (F), splenic CD45+CD3+CD8+ (G) and CD45+CD3+CD4+ T cells (H). VE, vehicle; PD1, anti-PD-1 day 1-4-7; PD11, anti-PD-1 day 11-14-17; CT, anti-CTLA-4 day 1-4-7; PD-1, programmed cell death-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.

抗小鼠CTLA-4单抗(9D9)在B16黑色素瘤模型中怎么给药?

1、用量参考

抗小鼠CTLA-4单克隆抗体(克隆号:9D9)在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。9D9抗体在设计使用进行体内研究时,确定其给药的最优剂量和方案是非常重要。根据现有文献报道,我们简要总结了抗小鼠CTLA-4单抗(9D9)在B16黑色素瘤模型 (B16 melanoma model) 中的给药方案,仅供参考。详情如下表(注意:手机左右滑动查看完整表格):

参数 描述
动物模型 B16 黑色素瘤小鼠模型
实验动物 C57BL/6 雌性或雄性小鼠(6-8 周龄)
给药途径 腹腔注射 (i.p.)
单只剂量 100-200 μg/次
给药间隔 每3天一次
总给药次数 3 次
动物数 5-10 只/组
起始时间 肿瘤接种后第 3-7 天
对照建议 相同亚型的同型对照IgG(如小鼠IgG2b)

* 以上为常见方案范围,最佳剂量与频次需结合动物状态与实验目的优化。

2、参考文献

1.Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1.Mok S, et al. Proc Natl Acad Sci U S A. 2025 Jan;122(2):e2418985122. doi: 10.1073/pnas.2418985122. PMID: 39786926

2.Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade.Blanchard L, et al. Cell Rep Med. 2025 Jun;6(6):102141. doi: 10.1016/j.xcrm.2025.102141. PMID: 40460830

3.Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells.Wang B, et al. Transl Cancer Res. 2021 Feb;10(2):899-913. doi: 10.21037/tcr-20-2738.

4.Anti–CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells.Selby MJ, et al. Cancer Immunol Res. 2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013. PMID: 24777248

5.Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.Phadke MS, et al. J Immunother Cancer. 2023 Dec;11(12):e007239. doi: 10.1136/jitc-2023-007239.

由于篇幅限制,以上仅展示了抗小鼠CTLA-4单克隆抗体(9D9)用于B16黑色素瘤模型的部分参考文献。如果您想要了解更多文献,欢迎联系我们(咨询微信:duozhaozhao2024)。

3、推荐产品

您是否在寻求价格合理、高质量的9D9抗体来推进您的研究?Syd Labs以提供体内实验级重组抗小鼠CTLA-4单克隆抗体(克隆号9D9)而闻名,如低内毒素(内毒素1 EU/mg)、极低内毒素(内毒素可低至0.05 EU/mg)、运用重组技术实现了不同分型的自由切换(小鼠版本、Fc沉默版本)。

查找Syd Labs 抗小鼠CTLA-4重组抗体(9D9)产品:抗小鼠CTLA-4单克隆抗体 (9D9)多种型

4、抗小鼠CTLA-4单抗(9D9)在不同小鼠肿瘤模型中的给药方案:

抗小鼠CTLA-4单抗(9D9)在B16黑色素瘤模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在MC38结肠腺癌模型中怎么给药?
9D9抗体在CT26结肠癌模型中怎么给药?
抗小鼠CTLA-4单抗(9D9)在Sa1N纤维肉瘤模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在EMT6乳腺癌模型中怎么给药?
9D9抗体在SW1黑色素瘤模型中怎么给药?
抗小鼠CTLA-4单抗(9D9)在TC1肺癌模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在ID8卵巢癌模型中怎么给药?
9D9抗体在胃肠道间质瘤模型中怎么给药?
抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在Hepa1-6肝细胞癌模型中怎么给药?
9D9抗体在不同小鼠肿瘤模型中怎么给药?